Review
Accepted on 15 Aug 2025
PART II -IMIDAZOLINES & RHINITIS MEDICAMENTOSA: How can we tackle the Rebound Dilemma?
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1655254
Type at least 3 characters
1,015 articles
Review
Accepted on 15 Aug 2025
Efficacy and safety of pregabalin in the management of low back pain: a comprehensive meta-analysis
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1659531
Original Research
Published on 15 Aug 2025
Global research trends on ALK-TKIs in non-small cell lung cancer: a bibliometric analysis
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1665174
- 334 views
Original Research
Accepted on 13 Aug 2025
Investigating the Feasibility of Machine Learning to Guide Personalized Red Blood Cell (RBC) Transfusion: Analyzing the Heterogeneity of RBC Transfusion in Septic Patients with Hemoglobin Levels of 7-9 g/dL Based on the Causal Forest Model
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1615618
- 137 views
Original Research
Accepted on 12 Aug 2025
Locked Nucleic Acid-Modified Antisense Oligonucleotides Attenuate Scar Hyperplasia through Targeted Inhibition of CTGF
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1623640
- 108 views
Original Research
Published on 12 Aug 2025
A case–control study on the individualized use of opioid analgesics based on single-nucleotide polymorphism
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1629866
- 277 views
Original Research
Accepted on 11 Aug 2025
Effect of ketamine on cellular immunity and inflammation in patients who undergo laparoscopic colon cancer surgery: A retrospective study
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1562122
- 356 views
Review
Accepted on 11 Aug 2025
Targeted Photodynamic Therapy: Enhancing Efficacy through Specific Organelle Engagement
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1667812
Review
Accepted on 11 Aug 2025
Retrospective Evaluation of Resident Pharmacists' Services in a Liver Intensive Care Unit: A Single-Center Experience
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1583818
Original Research
Accepted on 11 Aug 2025
Differential Carbon Source Utilization Drives Metabolic State and Resuscitation in Antibiotic-Tolerant Persister Cells
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1634627
Review
Published on 11 Aug 2025
From neuromodulation to bone homeostasis: therapeutic targets of nerve growth factor in skeletal diseases
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1614542
- 362 views
Original Research
Accepted on 04 Aug 2025
Published population pharmacokinetic models of mycophenolate sodium: a systematic review and external evaluation in a Chinese sample of renal transplant recipients
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1632568
Original Research
Published on 01 Aug 2025
Healthy participant engagement in early clinical trials: results from the European EUFEMED survey
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1540948
- 567 views
Original Research
Accepted on 31 Jul 2025
Pharmacokinetics and safety of highly variable Nitroglycerin Lingual Spray (NLS) versus US-Licensed Nitroglycerin Lingual Spray Reference Product (Nitrolingual®): a randomized, four-cycle, four-sequence, partially replicated crossover phase I bioequivalence clinical trial
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1631341
- 152 views
Original Research
Published on 31 Jul 2025
Ultrasound combined with microbubble enhanced renoprotective effects of NLRP3 inflammasome inhibitor MCC950 in CKD model
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1616542
- 313 views
Original Research
Accepted on 30 Jul 2025
Safety,Tolerability,Pharmacokinetics,Immunogenicity and Pharmacodynamics of 9MW1911, an Anti-ST2 Monoclonal Antibody: Results from a First-in-Human Phase 1 Study
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1647816
- 268 views